108 Institute of Clinical and Pharmaceutical Sciences, Hanoi, Vietnam.
Vietnamese-German Center for Medical Research (VG-CARE), Hanoi, Vietnam.
Ann Clin Microbiol Antimicrob. 2021 Sep 4;20(1):60. doi: 10.1186/s12941-021-00466-3.
Blood stream infections (BSI) caused by Extended Spectrum Beta-Lactamases (ESBLs) producing Enterobacteriaceae is a clinical challenge leading to high mortality, especially in developing countries. In this study, we sought to describe the epidemiology of ESBL-producing Escherichia coli strains isolated from Vietnamese individuals with BSI, to investigate the concordance of genotypic-phenotypic resistance, and clinical outcome of ESBL E. coli BSI.
A total of 459 hospitalized patients with BSI were screened between October 2014 and May 2016. 115 E. coli strains from 115 BSI patients were isolated and tested for antibiotic resistance using the VITEK®2 system. The ESBL phenotype was determined by double disk diffusion method following the guideline of Clinical and Laboratory Standards Institute. Screening for beta-lactamase (ESBL and carbapenemase) genes was performed using a multiplex-PCR assay.
58% (67/115) of the E. coli strains were ESBL-producers and all were susceptible to both imipenem and meropenem. Resistance to third-generation cephalosporin was common, 70% (81/115) were cefotaxime-resistant and 45% (52/115) were ceftazidime-resistant. bla was the most common ESBL gene detected (70%; 80/115) The sensitivity and specificity of bla-detection to predict the ESBL phenotype was 87% (76-93% 95% CI) and 54% (39-48% 95% CI), respectively. 28%% (22/80) of bla were classified as non-ESBL producers by phenotypic testing for ESBL production. The detection of bla in ESBL-negative E. coli BSI was associated with fatal clinical outcome (27%; 6/22 versus 8%; 2/26, p = 0.07).
A high prevalence of ESBL-producing E. coli isolates harbouring bla was observed in BSI patients in Vietnam. The genotypic detection of bla may have added benefit in optimizing and guiding empirical antibiotic therapy of E. coli BSI to improve clinical outcome.
产超广谱β-内酰胺酶(ESBLs)的肠杆菌科细菌引起的血流感染(BSI)是一个临床挑战,尤其是在发展中国家,导致高死亡率。在这项研究中,我们旨在描述从越南 BSI 患者中分离的产 ESBL 大肠埃希菌菌株的流行病学,调查 ESBL 大肠埃希菌 BSI 的基因型-表型耐药一致性和临床结局。
2014 年 10 月至 2016 年 5 月期间,共筛选了 459 名 BSI 住院患者。从 115 名 BSI 患者中分离出 115 株大肠埃希菌,并使用 VITEK®2 系统进行抗生素耐药性检测。ESBL 表型通过双倍纸片扩散法按照临床和实验室标准协会的指南进行确定。使用多重 PCR 检测β-内酰胺酶(ESBL 和碳青霉烯酶)基因。
58%(67/115)的大肠埃希菌菌株为 ESBL 生产者,对亚胺培南和美罗培南均敏感。对第三代头孢菌素的耐药性很常见,70%(81/115)对头孢噻肟耐药,45%(52/115)对头孢他啶耐药。bla 是最常见的 ESBL 基因(70%;80/115),检测 bla 预测 ESBL 表型的灵敏度和特异性分别为 87%(76-93%95%CI)和 54%(39-48%95%CI)。28%(22/80)的 bla 通过 ESBL 产生的表型检测被归类为非 ESBL 生产者。在 ESBL 阴性大肠埃希菌 BSI 中检测到 bla 与致命临床结局相关(27%;6/22 与 8%;2/26,p=0.07)。
在越南 BSI 患者中观察到携带 bla 的产 ESBL 大肠埃希菌分离株的高流行率。bla 的基因检测可能有助于优化和指导大肠埃希菌 BSI 的经验性抗生素治疗,以改善临床结局。